



IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

Document split into multiple parts

STATE OF OKLAHOMA, ex rel.,)
MIKE HUNTER,)
ATTORNEY GENERAL OF OKLAHOMA,)

Plaintiff,)

vs.)

- (1) PURDUE PHARMA L.P.;)
- (2) PURDUE PHARMA, INC.;)
- (3) THE PURDUE FREDERICK COMPANY;)
- (4) TEVA PHARMACEUTICALS USA, INC.;)
- (5) CEPHALON, INC.;)
- (6) JOHNSON & JOHNSON;)
- (7) JANSSEN PHARMACEUTICALS, INC;)
- (8) ORTHO-MCNEIL-JANSSEN)
PHARMACEUTICALS, INC., n/k/a)
- JANSSEN PHARMACEUTICALS;)
- (9) JANSSEN PHARMACEUTICA, INC.,)
n/k/a JANSSEN PHARMACEUTICALS, INC.;)
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,)
f/k/a ACTAVIS, INC., f/k/a WATSON)
PHARMACEUTICALS, INC.;)
- (11) WATSON LABORATORIES, INC.;)
- (12) ACTAVIS LLC; and)
- (13) ACTAVIS PHARMA, INC.,)
f/k/a WATSON PHARMA, INC.,)

Defendants.)

PART I

Case No. CJ-2017-816
Judge Thad Balkman

STATE OF OKLAHOMA } S.S.
CLEVELAND COUNTY }

FILED

MAY 23 2019

In the office of the
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1165	OKMB-17394- OKMB-17423	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1166	OKMB-17371-OKMB-17384-OKMB-17331-OKMB-17368	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1167	OKMB-7221- OKMB-7228	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1168	OKMB-7279- OKMB-7281	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1169	OKMB-7282- OKMB-7287	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1170	OKMB-11449- OKMB-11456	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1171	OBN-60171- OBN-60173	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1172	OSBOE-4809- OSBOE-4814	Order of Probation with Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1173	OKMB-7295- OKMB-7300	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1174	OKMB-7301- OKMB-7303	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1175	OKMB-7315- OKMB-7319	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1176	OSBOE-3758- OSBOE-3761	Findings of Fact, Conclusions of Law and Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1177	OSBOE-3762- OSBOE-3767	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1178	OBD-9454- OBD-9457	Agreed Order of Reprimand and Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1179	OBD-9471- OBD-9482	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1180	OKMB-36341- OKMB-36348	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1181	OKMB-7419- OKMB-7421	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1182	OKMB-7361- OKMB-7365	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1183	OKMB-7428- OKMB-7439	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1184	OKMB-7451- OKMB-7458	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1185	OBD-9560- OBD-9566	Final Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1186	OBD-16360- OBD-16362	Agreed Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J.&J and Janssen reserve the right to object at trial to any Teva exhibit because J.&J and Janssen have not had the opportunity to review them)
1187	OBD-9567- OBD-9569	Surrender Agreement	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1188	OKMB-11555- OKMB-11562	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1189	OKMB-5474- OKMB-5479	Voluntary Submittal to Jurisdiction and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1190	OKMB-5480- OKMB-5486	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1191	OKMB-11606- OKMB-11610	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1192	OSBOE-4437- OSBOE-4441	Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1193	OSBOE-4442- OSBOE-4446	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1194	OKMB-11671- OKMB-11675	Voluntary Surrender of License In Lieu of Prosecution With Waive of Right to Reapply	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1195	OKMB-11662- OKMB-11668	Amended Verified Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1196	OBN-61875- OBN-61901	Final Order Including Findings of Fact and Conclusion of Law	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1197	OKMB-12298- OKMB-12346	Order of Revocation of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1198	OKMB-17924- OKMB-17929	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1199	OKMB-12556- OKMB-12560	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1200	OSBOE-4453	Order accepting Surrender of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1201	OSBOE-4454- OSBOE-4458	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1202	OSBOE-985- OSBOE-989	Findings of Fact, Conclusions of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1203	OKMB-7538- OKMB-7540	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1204	OKMB-7541- OKMB-7548	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1205	OKMB-7586- OKMB-7596	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1206	OSBOE-1243- OSBOE-1245	Findings of Fact, Conclusions of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1207	OSBOE-1246- OSBOE-1253	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1208	OBN-60182- OBN-60185	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1209	OKMB-7611- OKMB-7618	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1210	OBD-9794- OBD-9799	Agreed Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1211	OKMB-12578- OKMB-12581	Order Granting Motion For Default Judgment And Revocation of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1212	OKMB-12564- OKMB-12568	Verified Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1213	OKMB-7657- OKMB-7664	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1214	OKMB-7645- OKMB-7653	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1215	OBD-9842- OBD-9848	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1216	OSBOE-1259- OSBOE-1262	2008 Resignation Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1217	OSBOE-1265- OSBOE-1269	Emergency Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1218	OSBOE-997- OSBOE-998	Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1219	OSBOE-999- OSBOE-1011	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1220	OKMB-7719- OKMB-7721-	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1221	OKMB-17939- OKMB-17941	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1222	OKMB-12593- OKMB-12598	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1223	OKMB-36379- OKMB-36387	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1224	OKMB-12634- OKMB-12646	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1225	OBD-9888- OBD-9891	Agreed Order of Suspension and Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1226	OBD-9900- OBD-9906	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1227	OKMB-7798- OKMB-7801	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1228	OKMB-7802- OKMB-7804	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1229	OSBOE-1236- OSBOE-1239	Emergency Order of Suspension Pending Hearing	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1230	OKMB-12676- OKMB-12682	Order of Indefinite Suspension of License Pending Evaluation and Board Approval	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1231	OKMB-6222- OKMB-6229	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1232	OKMB-7833- OKMB-7847	Final Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1233	OKMB-7848- OKMB-7853	Final Order of Suspension, Restriction, Administrative Fine and Community Service	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1234	OBN-60455- OBN-60463	Order to Show Cause	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1235	OBN-60464- OBN-60466	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1236	OBN-60479- OBN-60484	Notice of Hearing and Order to Show Cause	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1237	OBN-60467	Voluntary Surrender of Controlled Substances Privileges	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1238	OBN-60485- OBN-60488	Immediate suspension Due to Imminent Danger	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1239	OSBOE-5084	Order Accepting Voluntary Surrender of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1240	OSBOE-5085- OSBOE-5089	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1241	OSBOE-4536- OSBOE-4539	Probation Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1242	OSBOE-4540- OSBOE-4541	Emergency Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1243	OSBOE-4542- OSBOE-4546	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1244	OKMB-36476- OKMB-36478	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1245	OKMB-36479- OKMB-36482	Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1246	OKMB-36483- OKMB-36489	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1247	OKMB-12932- OKMB-12940	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1248	OKMB-36497- OKMB-36508	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1249	OBN-60149- OBN-60155	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1250	OKMB-18029- OKMB-18031	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1251	OKMB-36514- OKMB-36521	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1252	OKMB-6230- OKMB-6238	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because I&J and Janssen have not had the opportunity to review them)
1253	OSBOE-1023- OSBOE-1028	Findings of Fact, Conclusions of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1254	OBN-60489- OBN-60493	Immediate Suspension Due to Imminent Danger	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1255	OSBOE-1284- OSBOE-1286	Findings of Fact, Conclusions of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1256	OSBOE-1298	Affidavit for Surrender of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1257	OSBOE-1299- OSBOE-1303	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1258	OKMB-12952- OKMB-12956	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1259	Publicly Available	Superseding Information - <i>United States of America v. Amar Nath Bhandary</i> ;	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1260	Publicly Available	Plea Agreement- <i>United States of America v. Amar Nath Bhandary</i> ;	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1261	OKAG-00137824 - OKAG-00137827	Information - <i>State of Oklahoma v. George J. Blake</i> ; Dist. Ct. of Tulsa County	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
1262	OKAG-00137835 - OKAG-00137841	Plea of Guilty - <i>State of Oklahoma v. George J. Blake</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
1263	OKAG-00138496 – OKAG-00138503	3 rd Amended Bind-Over Information – <i>State of Oklahoma v. David P. Crass</i> ;	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1264	OKAG-00138639 – OKAG-00138649	Judgment and Sentence - <i>State of Oklahoma v. David P. Crass</i> ;	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1265	OKAG-00137804 – OKAG-00137806	Information - <i>State of Oklahoma v. Addie Beth Gratz and Azuka Cassandra Egbunive</i> ;	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1266	Publicly Available	Oklahoma Attorney General Press Release	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1267	OKAG-00137845 – OKAG-00137847	Indictment – <i>State of Oklahoma v. Jerri Lynn Ellis and Dennis Lee Roberts</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1268	Publicly Available	Oklahoma Attorney General Press Release	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1269	Publicly Available	Indictment – <i>United States of America v. Dr. James M. Ferris, MD, Katherine Dossey, and Sherry Isbell</i> ;	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1270	OKAG-00138204 – OKAG-00138207	Information – <i>State of Oklahoma v. James Lawrence Fleckenstein, MD</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
1271	OKAG-00138229 - OKAG-00138243	Plea of Guilty - <i>State of Oklahoma v. James Lawrence Fleckenstein, MD</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403. Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403. Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1272		Oklahoma Attorney General Press Release n	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1273	OKAG-00137868 - OKAG-00137896	Information - <i>State of Oklahoma v. Bernard M. Tougas, Ronald V. Myers, and George B. Howell, MD</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1274	OKAG-00145612 - OKAG-00145620	Oklahoma Bureau of Narcotics ACISS Investigative Supplement	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403. Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1275	OKAG-00138821 - OKAG-00138862	Third Amended Information - <i>State of Oklahoma v. Harvey Clarke Jenkins, Jr., MD</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403. Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1276	OKAG-00138696 - OKAG-00138702	Amended Information - <i>State of Oklahoma v. Regan Ganoung Nichols</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1277	Publicly Available	Oklahoma Attorney General Press Release	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1278	Publicly Available	Oklahoma Attorney General Press Release	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1279	Publicly Available	Information – <i>State of Oklahoma v. William Kerry Smith</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1280	Publicly Available	Amended Deferral – <i>State of Oklahoma v. William Kerry Smith</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1281	Publicly Available	Indictment – <i>United States of America v. Dr. Melvin Lee Robinson, DO and Mohab Hallaba, MD</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1282	Publicly Available	Indictment – <i>United States of America v. Ian Alexander Bowline</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1283	Publicly Available	Criminal Complaint – <i>United States of America v. Ian Alexander Bowline</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1284	Publicly Available	Verdict Form – <i>United States of America v. Ian Alexander Bowline</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1285	Publicly Available	Indictment – <i>United States of America v. Jeremy David Thomas and Chad Lee Choat</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1286	Publicly Available	Petition To Enter Plea of Guilty And Order Entering Plea – <i>United States of America v. Jeremy David Thomas and Chad Lee Choat</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1287	Publicly Available	Indictment – <i>United State of America v. Jeremy David Thomas and Jeffrey Lee Koger</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1288	Publicly Available	Petition To Enter Plea of Guilty And Order Entering Plea – <i>United State of America v. Jeremy David Thomas and Jeffrey Lee Koger</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1289	Publicly Available	Indictment – <i>United State of America v. Jeremy David Thomas and Joseph Marcus Jones</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1290	Publicly Available	Petition To Enter Plea of Guilty And Order Entering Plea – <i>United State of America v. Jeremy David Thomas and Joseph Marcus Jones</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1291	Publicly Available	Indictment – <i>United State of America v. Jeremy David Thomas and Toni Dawn Martin</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1292	Publicly Available	Petition To Enter Plea of Guilty And Order Entering Plea – <i>United State of America v. Jeremy David Thomas and Toni Dawn Martin</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1293	Publicly Available	Indictment – <i>United State of America v. Jeremy David Thomas and Shawn Del Martin</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1294	Publicly Available	Petition To Enter Plea of Guilty And Order Entering Plea – <i>United State of America v. Jeremy David Thomas and Shawn Del Martin</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1295	Attached as Exhibit B(1)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1296	Attached as Exhibit B(1)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1297	Attached as Exhibit B(2)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1298	Attached as Exhibit B(3)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1299	Attached as Exhibit B(4)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1300	Attached as Exhibit B(5)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1301	Attached as Exhibit B(6)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1302	Attached as Exhibit B(6)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1303	Attached as Exhibit B(6)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1304	Attached as Exhibit B(6)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1305	Attached as Exhibit B(7)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1306	Attached as Exhibit B(7)	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1307	OSBP 239405	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1308	OSBP 239407	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1309	OSBP 239406	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1310	OSBP 239376	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1311	OSBP 239377	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1312	OSBP 239377	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1313	OSBP 239377	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1314	OSBP 239326	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1315	OSBP 239327	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1316	OSBP 239327	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1317	OSBP 239273	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1318	OSBP 239272-239273	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1319	OSBP 239271	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1320	OSBP 239272	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1321	OSBP 239271	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1322	OSBP 239229	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1323	OSBP 239207	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1324	OSBP 239151	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1325	OSBP 239151	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1326	OSBP 239124	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1327	OSBP 239099	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1328	OSBP 239099	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1329	OSBP 239100	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1330	OSBP 239072	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1331	OSBP 239071	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1332	OSBP 239073	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1333	OSBP 239072	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1334	OSBP 239024	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1335	OSBP 239024	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1336	OSBP 239005	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1337	OSBP 238978	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1338	OSBP 238950-238951	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1339	OSBP 238949	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1340	OSBP 238925	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1341	OSBP 238925	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1342	OSBP 238899	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1343	OSBP 238899	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1344	OSBP 238878	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1345	OSBP 238854-238855	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1346	OSBP 238854	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1347	OSBP 238854	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1348	OSBP 238853	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1349	OSBP 238835	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1350	OSBP 238834	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1351	OSBP 238834	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1352	OSBP 238808	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1353	OSBP 238807-238808	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1354	OSBP 238807	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1355	OSBP 238805-238806	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1356	OSBP 238789	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1357	OSBP 238788	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1358	OSBP 238474	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1359	OSBP 238746	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1360	OSBP 238745	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1361	OSBP 238745	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1362	OSBP 238745	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1363	OSBP 238729	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1364	OSBP 238701	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1365	OSBP 238627	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1366	OSBP 238602-238603	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1367	OSBP 238602	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1368	OSBP 238601	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1369	OSBP 238600-238601	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1370	OSBP 238600	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1371	OSBP 238574	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1372	OSBP 238557	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1373	OSBP 238557	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1374	OSBP 238556-238557	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1375	OSBP 238533	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1376	OSBP 238532	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1377	OSBP 238531	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1378	OSBP 238530	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1379	OSBP 238507	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1380	OSBP 238505	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1381	OSBP 238505	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1382	OSBP 238483	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1383	OSBP 238483	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1384	OSBP 238482	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1385	OSBP 238482	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1386	OSBP 238482	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1387	OSBP 238482	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1388	OSBP 238466	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1389	OSBP 238466	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1390	OSBP 238465	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1391	OSBP 238444	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1392	OSBP 238443	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1393	OSBP 238443	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1394	OSBP 238422	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1395	OSBP 238403	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1396	OSBP 238393	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1397	OSBP 238393	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1398	OSBP 238391	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1399	OSBP 238391	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1400	OSBP 238367	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1401	OSBP 238328	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1402	OSBP 238327	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1403	OSBP 238326	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1404	OSBP 238307	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1405	OSBP 238304	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1406	OSBP 238244	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1407	OSBP 238221	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J.&J and Janssen reserve the right to object at trial to any Teva exhibit because J.&J and Janssen have not had the opportunity to review them)
1408	Attached as Exhibit B(8)	Complaint in Case No. 3801, Board of Pharmacy, State of California	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1409	OSBP 238207	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1410	OSBP 238183	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1411	OSBP 238175	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1412	OSBP 238141	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1413	Attached as Exhibit B(9)	OSBP Complaint in Case No. 926	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1414	OSBP 238047	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1415	OSBP 238032	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1416	OSBP 237825	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1417	OSBP 237703	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1418	OSBP 237703	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1419	OSBP 237674	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1420	OSBP 237637	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1421	OSBP 237636	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1422	OSBP 237636	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1423	OSBP 237469-237470	"Tramadol Abuse Information"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403, J-MIL #17
1424	OSBP 237470	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1425	Attached as Exhibit B(10)	Final Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1426	OSBP 237442-237443	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1427	OSBP 237442	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1428	OSBP 237441-237442	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1429	OSBP 237367	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1430	OSBP 237366	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1431	OSBP 237278	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1432	OSBP 237278	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1433	OSBP 237277	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1434	OSBP 237235	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1435	OSBP 237177	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1436	OSBP 237177	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1437	OSBP 237133	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1438	OSBP 237101	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1439	Attached as Exhibit B(11)	<i>U.S. v. Fuchs</i> , 467 F.3d 889 (5th Cir. 2006)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1440	Attached as Exhibit B(12)	PACER Docket in Criminal Case 5:01-cr-00142-R	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1441	OSBP 236942	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1442	OSBP 236655-236656	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1443	OSBP 236628-236629	OSBP Minutes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1444	Attached as Exhibit B(13)	Oklahoma Bureau of Narcotics Press Release	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1445	Attached as Exhibits B(14)-(B)(38)	U.S. v. Compton et al	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1446	Attached as Exhibit B(39)	Oklahoma Bureau of Narcotics Press Release	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1447	Publicly Available	United States v. Melvin Lee Robinson and Moheb Hallaba. Indictment	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1448	Publicly Available	United States v. James Ferris, Katherine Dossey, and Sherry Isbell, Indictment	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1449	OBN-00206616	Oklahoma Bureau of Narcotics & Dangerous Drugs Control Executive Summary	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1450	OBN-00111383	Oklahoma State Drug Threat Assessment Annual Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1451	OBN-00051892	Oklahoma State Drug Threat Assessment Annual Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1452	Publicly Available	2002 DEA Oklahoma Drug Threat Assessment	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1453	Publicly Available	OBN Press Release "Program Being Launched to Halt Doctor Shoppers"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1454	Publicly Available	Fact Sheet Fentanyl	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
1455	Publicly Available	Fact Sheet Prescription Opioids	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1456	Publicly Available	House Bill 2795	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1457	Publicly Available	Oklahoma Watch- "Profiting from Pain: Clinics Help Fuel Prescription Pill Epidemic."	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1458	Publicly Available	OBN Bureau Names "Legislators of the Year"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1459	Publicly Available	OBN "State Drug Agency Working to Curb Overdose Deaths"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1460	Publicly Available	OBN "Narcotics Bureau Addresses Alarming Trend Involving Prescription Drug Deaths"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1461	Publicly Available	OBN "Narcotics Bureau Safety Disposes More Than 3 Tons of Drugs from Permanent Drop Box Sites"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1462	Publicly Available	Fact Sheet on Prescription Drug Abuse, Misuse and Consequences Among Oklahoma	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1463	Publicly Available	OBN "Prescription Drug Abuse Awareness Week" Press Conference	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1464	Publicly Available	Senate Bill 1124	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1465	Publicly Available	Senate Bill 1267	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1466	Publicly Available	OBN "Narcotics Bureau to Announce Student Prescription Drug Abuse Awareness Contest Winners"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1467	Publicly Available	OBN "State and Local Authorities Uncover and Halt Prescription Drug Scheme Inside Sulphur Nursing Home."	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1468	Publicly Available	OBN "Eastern Oklahoma Physician's Assistant Arrested on Drug Charges"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1469	Publicly Available	Fact Sheet Heroin	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1470	OKAGSS_00110340	Patient 264620 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1471	OKAGSS_00071942	Patient 273627 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1472	OKAGSS_00110079	Patient 730357 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1473	OKAGSS_00285299	Patient 615779 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1474	OKAGSS_00048969	Patient 218635 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1475	OKAGSS_00077765	Patient 365344 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1476	OKAGSS_00008166	Patient 227150 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1477	OKAGSS_00008207	Patient 227150 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1478	OKAGSS_00008315	Patient 227150 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1479	OKAGSS_00008459	Patient 227150 Records	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1480	[OKAG-00013555-13636]	DURB Meeting Packet, Apr. 10, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1481	[OKAG-00013637-13714]	DURB Meeting Packet, Apr. 11, 2012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1482	[OKAG-00009939-10093]	DURB Meeting Packet, Apr. 11, 2018	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1483	[OKAG-00013715-13780]	DURB Meeting Packet, Apr. 12, 2005	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1484	[OKAG-00005975-6045]	DURB Meeting Packet, Apr. 12, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1485	[OKAG-00009783]	DURB Meeting Packet, Apr. 12, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1486	[OKAG-00012164-12224]	DURB Meeting Packet, Apr. 13, 2004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1487	[OKAG-00013781-13894]	DURB Meeting Packet, Apr. 13, 2011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1488	[OKAG-00008351-8520]	DURB Meeting Packet, Apr. 13, 2016	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1489	[OKAG-0000555-613]	DURB Meeting Packet, Apr. 8, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1490	[OKAG-00011432-11533]	DURB Meeting Packet, Apr. 9, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1491	[OKAG-00012447-12511]	DURB Meeting Packet, Aug. 10, 2005	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1492	[OKAG-00014174-14274]	DURB Meeting Packet, Aug. 10, 2011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1493	[OKAG-00001069-11118]	DURB Meeting Packet, Aug. 12, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1494	[OKAG-00014275-14361]	DURB Meeting Packet, Aug. 14, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1495	[OKAG-00001121-1173]	DURB Meeting Packet, Aug. 8, 2012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1496	[OKAG-00004814-4931]	DURB Meeting Packet, Dec. 10, 2008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1497	[OKAG-0001110-1183]	DURB Meeting Packet, Dec. 10, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1498	[OKAG-00015075-15123]	DURB Meeting Packet, Dec. 11, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1499	[OKAG-00008039-8108]	DURB Meeting Packet, Dec. 13, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1500	[OKAG-00009251-9392]	DURB Meeting Packet, Dec. 13, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1501	[OKAG-00012758-12833]	DURB Meeting Packet, Dec. 14, 2004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1502	[OKAG-00007891-7948]	DURB Meeting Packet, Dec. 14, 2005	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1503	[OKAG-00015124-15182]	DURB Meeting Packet, Dec. 14, 2011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1504	[OKAG-00007724-7890]	DURB Meeting Packet, Dec. 16 2015	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1505	[OKAG-00015011-15044]	DURB Meeting Packet, Dec. 8, 2010	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1506	[OKAG-00000139-190]	DURB Meeting Packet, Feb. 11, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1507	[OKAG-00003929-4004]	DURB Meeting Packet, Feb. 12, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1508	[OKAG-00001828-1890]	DURB Meeting Packet, Feb. 13, 2008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1509	[OKAG-00013377-13429]	DURB Meeting Packet, Feb. 13, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1510	[OKAG-00009524-9673]	DURB Meeting Packet, Feb. 14, 2018	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1511	[OKAG-00011979-12038]	DURB Meeting Packet, Feb. 8, 2005	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1512	[OKAG-00005681-5743]	DURB Meeting Packet, Feb. 8, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1513	[OKAG-00000253-304]	DURB Meeting Packet, Feb. 8, 2012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1514	[OKAG-00005500-5561]	DURB Meeting Packet, Jan. 11, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1515	[OKAG-00005562-5614]	DURB Meeting Packet, Jan. 9, 2008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1516	[OKAG-00011866-11944]	DURB Meeting Packet, Jan. 11, 2005	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1517	[OKAG-00011806-11865]	DURB Meeting Packet, Jan. 13, 2004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1518	[OKAG-00015460-15519]	DURB Meeting Packet, Jan. 14, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1519	[OKAG-00014022-14107]	DURB Meeting Packet, Jul. 10, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1520	[OKAG-00014108-14173]	DURB Meeting Packet, Jul. 11, 2012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1521	[OKAG-00006431-6487]	DURB Meeting Packet, Jul. 12, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1522	[OKAG-00010602-10792]	DURB Meeting Packet, Jul. 12, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1523	[OKAG-00008610-8749]	DURB Meeting Packet, Jul. 13, 2016	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1524	[OKAG-00003808-3926]	DURB Meeting Packet, Jul. 8, 2015	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1525	[OKAG-00004723-4813]	DURB Meeting Packet, Jul. 9, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1526	[OKAG-00010556-10601]	DURB Meeting Packet, Jun. 10, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1527	[OKAG-00012966-13075]	DURB Meeting Packet, Jun. 11, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1528	[OKAG-00004307-4381]	DURB Meeting Packet, Jun. 11, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J.&J and Janssen reserve the right to object at trial to any Teva exhibit because J.&J and Janssen have not had the opportunity to review them)
1529	[OKAG-00010215-10394]	DURB Meeting Packet, Jun. 8, 2016	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1530	[OKAG-00000821-885]	DURB Meeting Packet, June 9, 2010	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1531	[OKAG-00000375-443]	DURB Meeting Packet, Mar. 10, 2010	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1532	[OKAG-00000308-372]	DURB Meeting Packet, Mar. 11, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1533	[OKAG-00011345-11429]	DURB Meeting Packet, Mar. 11, 2015	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1534	[OKAG-00000445-552]	DURB Meeting Packet, Mar. 12, 2008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1535	[OKAG-00013430-13515]	DURB Meeting Packet, Mar. 13, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1536	[OKAG-00013516-13554]	DURB Meeting Packet, Mar. 14, 2012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1537	[OKAG-00004601-4722]	DURB Meeting Packet, Mar. 14, 2018	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1538	[OKAG-00005829-5893]	DURB Meeting Packet, Mar. 8, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1539	[OKAG-00009675-9782]	DURB Meeting Packet, Mar. 8, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1540	[OKAG-00012039-12087]	DURB Meeting Packet, Mar. 9, 2004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1541	[OKAG-00013151-13225]	DURB Meeting Packet, Mar. 9, 2011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1542	[OKAG-00008237-8347]	DURB Meeting Packet, Mar. 9, 2016	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1543	[OKAG-00006122-6184]	DURB Meeting Packet, May 10, 2005	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1544	[OKAG-00010094-10214]	DURB Meeting Packet, May 10, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1545	[OKAG-00013226-13302]	DURB Meeting Packet, May 11, 2011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1546	[OKAG-00000754-818]	DURB Meeting Packet, May 14, 2008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1547	[OKAG-00004424-4541]	DURB Meeting Packet, May 14, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1548	[OKAG-00006046-6121]	DURB Meeting Packet, May 9, 2007	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1549	[OKAG-00014799-14833]	DURB Meeting Packet, Nov. 10, 2010	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1550	[OKAG-00010911-10961]	DURB Meeting Packet, Nov. 12, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1551	[OKAG-00010964-11033]	DURB Meeting Packet, Nov. 12, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1552	[OKAG-00014834-14950]	DURB Meeting Packet, Nov. 13, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1553	[OKAG-00014951-15010]	DURB Meeting Packet, Nov. 14, 2012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1554	[OKAG-00007599-7656]	DURB Meeting Packet, Nov. 8, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1555	[OKAG-00012703-12757]	DURB Meeting Packet, Nov. 9, 2004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1556	[OKAG-00007348-7415]	DURB Meeting Packet, Oct. 10, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1557	[OKAG-00007416-7491]	DURB Meeting Packet, Oct. 11, 2006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1558	[OKAG-00007137-7286]	DURB Meeting Packet, Oct. 12, 2016	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1559	[OKAG-00009037-9099]	DURB Meeting Packet, Oct. 14, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1560	[OKAG-00006981-7133]	DURB Meeting Packet, Oct. 14, 2015	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1561	[OKAG-00005085-5306]	DURB Meeting Packet, Oct. 4, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1562	[OKAG-00012635]	DURB Meeting Packet, Oct. 6, 2004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1563	[OKAG-00015183-15256]	DURB Meeting Packet, Oct. 8, 2014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1564	[OKAG-00006637-6710]	DURB Meeting Packet, Sep. 12, 2007	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1565	[OKAG-00014362-14431]	DURB Meeting Packet, Sep. 12, 2012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1566	[OKAG-00003307-5499]	DURB Meeting Packet, Sep. 13, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1567	[OKAG-00014432-14500]	DURB Meeting Packet, Sep. 14, 2011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1568	[OKAG-00010793-10910]	DURB Meeting Packet, Sep. 14, 2017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1569	[OKAG-00015257-15336]	DURB Meeting Packet, Sep. 8, 2010	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1570	[OKAG-00001174-1253]	DURB Meeting Packet, Sep. 9, 2009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1571	[OKAG-00014501-14545]	DURB Online Packet, Oct. 1, 2013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1572	OKAG-00001069	8/12/2009 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1573	OKAG-00004601	3/14/2018 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1574	OKAG-00006981	9/9/2015 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1575	OKAG-00007137	9/14/2016 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1576	OKAG-00009037	10/14/2009 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1577	OKAG-00010602	7/12/2017 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1578	OKAG-00012039	3/9/2004 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1579	OKAG-00012703	10/12/2004 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1580	OKAG-00012966	6/12/2013 DURB Meeting Packet	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1581	OHCA-00085862	1/13/2004 Post-DURB Meeting Notes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1582	EGID-00000141	egid_export_file_20180619	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1583	EGID-00000142	EGID Medical Claims Field Names	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1584	EGID-00000143	EGID Medical DXC 2009 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1585	EGID-00000144	EGID Medical DXC 2009 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1586	EGID-00000145	EGID Medical DXC 2009 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1587	EGID-00000146	EGID Medical DXC 2009 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1588	EGID-00000147	EGID Medical DXC 2009 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1589	EGID-00000148	EGID Medical DXC 2009 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1590	EGID-00000149	EGID Medical DXC 2010 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1591	EGID-00000150	EGID Medical DXC 2010 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1592	EGID-00000151	EGID Medical DXC 2010 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1593	EGID-00000152	EGID Medical DXC 2010 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1594	EGID-00000153	EGID Medical DXC 2010 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1595	EGID-00000154	EGID Medical DXC 2010 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1596	EGID-00000155	EGID Medical DXC 2011 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1597	EGID-00000156	EGID Medical DXC 2011 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1598	EGID-00000157	EGID Medical DXC 2011 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1599	EGID-00000158	EGID Medical DXC 2011 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1600	EGID-00000159	EGID Medical DXC 2011 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1601	EGID-00000160	EGID Medical DXC 2011 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1602	EGID-00000161	EGID Medical DXC 2012 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1603	EGID-00000162	EGID Medical DXC 2012 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1604	EGID-00000163	EGID Medical DXC 2012 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1605	EGID-00000164	EGID Medical DXC 2012 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1606	EGID-00000165	EGID Medical DXC 2012 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1607	OHCA-00000001	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1608	OHCA-00000002	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1609	OHCA-00445507	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1610	OHCA-00445508	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1611	OHCA-00445496	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1612	OHCA-00445497	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1613	OHCA-00445498	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1614	OHCA-00445499	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1615	OHCA-00445500	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1616	OHCA-00445501	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1617	OHCA-00445502	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1618	OHCA-00445503	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1619	OHCA-00445512	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1620	OHCA-00445513	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1621	OHCA-00445514	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1622	OHCA-00445515	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1623	OHCA-00445516	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1624	OHCA-00445517	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1625	OHCA-00445518	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1626	OHCA-00445519	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1627	OHCA-00445520	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
1628	OHCA-00445521	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1629	OHCA-00445522	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1630	OHCA-00445523	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1631	OHCA-00445524	Documents related to Oklahoma Medicaid prescriptions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1632	ODMHSAS-00000273	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1633	ODMHSAS-00000274	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1634	ODMHSAS-00000275	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1635	ODMHSAS-00000276	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1636	ODMHSAS-00037879	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1637	ODMHSAS-00037880	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1638	ODMHSAS-00037881	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1639	ODMHSAS-00037882	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1640	ODMHSAS-00037883	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1641	ODMHSAS-00037884	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1642	ODMHSAS-00038070	Documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1643	OSMA_OK_00000949-OSMA-000000956	The Journal of the Oklahoma State Medical Association	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1644	OSMA_OK_000006506	Email Re: PMP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1645	OSMA_OK_00007226	Email from OK Osteo to OSMA	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1646	OSMA_OK_00007173-OSMA-00007178	Email Re: PMP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1647	OSMA_OK_00008217-OSMA-00008219	Email Re: PMP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1648	OSMA_OK_00008220- OSMA-00008221	Email from Ken King	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1649	OSMA_OK_00065826- OSMA-00065827	Email from Lori Carter	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1650	OSMA_OK_00110816- OSMA-00110830	Email from Patrick Hall	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1651	OSMA_OK_00007236-OSMA-00007237	American Cancer Society Letter	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1652	OSMA_OK_00038915-OSMA-00038916	Email Re: Stolen RX Protocols	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1653	OSMA_OK_00062887	Email from Patrick Hall	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1654	OSMA_OK_00063147	Email from Patrick Hall	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1655	OSMA_OK_00063148	Email Re: Political Contribution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1656	OSMA_OK_00063171	Email Re: Political Contribution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1657	OSMA_OK_00063175	Email Re: Political Contribution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1658	OSMA_OK_00066913-OSMA-00066915	Email Re: narcotic issue	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1659	OSMA_OK_00090107-OSMA-00090109	Email Re: AG Press Release	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1660	OSMA_OK_00090724-OSMA-00090725	Executive Committee Notes	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1661	OSMA_OK_00117687-OSMA-00117688	Email from Patrick Hall	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1662	OSMA_OK_0011858	Email chain Matt Robinson	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1663	OSMA_OK_00118573-OSMA-00118574	Email chain Matt Robinson	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2000	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/207471bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2001	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20747s017bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2002	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020747s019bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2003	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020747s023bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
2004	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020747s027lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2005	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020747s030lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2006	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020747s029lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2007	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020747s033lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2008	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020747s043s044lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2009	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021947lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2010	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021947s006lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2011	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021947s010lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2012	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021947s011lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2013	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021947s009lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2014	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021947s013lbl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
2015	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021947s015bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2016	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021947s024s025bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
2017	Publicly Available	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s019bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
3000	TEVA_OK_04745022	Cephalon Corporate Integrity Agreement	12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
3001	Cephalon Motion for Partial Summary Judgment Exhibit 1-B	Signed Cephalon Settlement Agreement	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4000	TEVA_OK_06205249	Cephalon Sales Policy Handbook	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4001	TEVA_OK_00852658	Cephalon Sales Policy Handbook	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4002	TEVA_OK_03529966	Cephalon Sales Policy Handbook	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4003	TEVA_OK_00510390	Cephalon US Sales and Marketing Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4004	TEVA_OK_00510853	Teva Integrity Principles Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4005	TEVA_OK_05391824	Memo from Roy Craig to U.S. Sales	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4006	TEVA_OK_01358396	Cephalon Targeting Assessment and Call Activity	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4007	TEVA_OK_00097186	Cephalon Targeting Assessment and Call Activity	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
4008	TEVA_OK_00510295	Standards of Global Business Practices	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4009	TEVA_OK_00510826	Teva Code of Business Conduct	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4010	TEVA_OK_03039249	PCS Sales Leadership Kick-Off Meeting	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4011	TEVA_OK_07969710	Policy on Providing Reimbursement Information to Customers	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4012	TEVA_OK_03033132	National Sales Meeting Presentation	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4013	TEVA_OK_00008656	Reimbursement Process and Procedure Guide	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4014	TEVA_OK_00510198	Cephalon Reimbursement Process and Procedure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4015	TEVA_OK_08163456	FENTORA CII Regional Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4016	TEVA_OK_00591635	Reimbursement Process and Procedure Guide	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4017	TEVA_OK_08136570	ACTIQ Reimbursement Hotline	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4018	TEVA_OK_00610450	Pain Care Business Overview	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4019	TEVA_OK_01155832	A Brand New Day: TEVA Pain Care 180-Day Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4020	TEVA_OK_01418073	Cephalon Sales Department Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4021	TEVA_OK_08482131	Reimbursement Process and Procedure Guide	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4022	TEVA_OK_00118889	How Do I Request Additional Information About FENTORA?	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
4023	TEVA_OK_00124029	Cephalon Sales Training & Development Phase II Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4024	TEVA_OK_03530052	Sales Policy Handbook – Policy on Providing Reimbursement Information to Customers	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4025	Publicly Available	Letter to Thomas Willer (FDA) re: NDA 20-747	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4026	Publicly Available	Letter to John Markow (FDA) re NDA 20-747	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4027	TEVA_OK_00094174	Actiq Master Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4028	TEVA_OK_00094235	Actiq Marketing	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4029	TEVA_OK_05721489	Actiq Breakthrough Pain Learning System	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4030	TEVA_OK_02269147	Cephalon Marketing Department Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4031	TEVA_OK_01418073	Cephalon Marketing Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4032	TEVA_OK_02269143	Cephalon Pharmaceutical Operations Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4033	TEVA_OK_00094243	Actiq 2002 Marketing Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4034	TEVA_OK_00094299	Actiq 2003 Marketing Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4035	TEVA_OK_00094368	2004 Actiq Marketing Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4036	TEVA_OK_00094427	2005 Actiq Marketing Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4037	TEVA_OK_03045793	ACTIQ 2006 Marketing Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4038	TEVA_OK_00116240	A Pain Primer: A Reference for the Rest of Us	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4039	TEVA_OK_02614471	Actiq Marketing Materials – Promotional	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4040	TEVA_OK_00350820	Actiq Promotional Guidelines (2005)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J.&J and Janssen have not had the opportunity to review them)
4041	TEVA_OK_07226733	ACTIQ New Hire Kit	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4042	TEVA_OK_03758143	FEBT Launch Playbook	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4043	TEVA_OK_00095084	FEBT (Fentanyl Effervescent Buccal Tablet) 2005-2006 Marketing Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4044	TEVA_OK_00039264	OVF Commercial Strategy Meeting	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4045	TEVA_OK_00041496	Sales Training on the RiskMAP	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4046	TEVA_OK_00059247	FENTORA Launch Agenda	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4047	TEVA_OK_00095380	Marketing Plan 2007	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4048	TEVA_OK_00095325	2008 Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4049	TEVA_OK_00065371	FENTORA 90 Day Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4050	TEVA_OK_00058933	Pre-module: Introduction to Pain	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4051	TEVA_OK_00095327	FENTORA 2009 Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4052	TEVA_OK_01084820	FENTORA 2009 National Sales Meeting	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4053	TEVA_OK_00095381	FENTORA 2010 Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4054	TEVA_OK_00095061	FENTORA 2011 Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4055	TEVA_OK_00122863	Media Fact Sheet: FENTORA	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
4056	TEVA_OK_02623052	2012 FENTORA Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4057	TEVA_OK_02618215	FENTORA Brand Review	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4058	TEVA_OK_01132830	Fast Start Meeting	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4059	TEVA_OK_01258074	FENTORA Prescription Savings Card Brochure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4060	TEVA_OK_00855354	CNS: Fentora 2014 Annual Operating Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4061	TEVA_OK_08308056	FENTORA US Regional Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4062	TEVA_OK_01024590	Fentora Questions & Answers for Patients	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4063	TEVA_OK_01055618	FENTORA Reimbursement Kit	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4064	TEVA_OK_08308056	FENTORA US Regional Brand Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4065	TEVA_OK_00399651	Cephalon Incentive Compensation Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4066	TEVA_OK_00509905	Cephalon Employee Compensation Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4067	TEVA_OK_00097186	Cephalon Employee Incentive Compensation Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4068	TEVA_OK_01167677	Teva 2014 North America Specialty Medicines President's Club Awards	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4069	TEVA_OK_00919090	Employee Incentive Compensation Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4070	TEVA_OK_09615881	Cephalon Management Incentive Compensation Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J.&J and Janssen reserve the right to object at trial to any Teva exhibit because J.&J and Janssen have not had the opportunity to review them)
4071	TEVA_OK_01039409	PCS New Hire Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4072	TEVA_OK_00919090	Incentive Compensation for Covered Persons	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4073	Acquired_Actavis_02228429	Morphine Sulfate ER Caps	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4074	Acquired_Actavis_01372605	Oxymorphone ER Journal Ad	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4075	Acquired_Actavis_02230003	Oxymorphone HCL Extended Release Tabs	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4076	Acquired_Actavis_01325827	Regional Meetings: Generic Kadian® Sales Team Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4077	Acquired_Actavis_02231065	Infolert: Watson/Actavis Acquisition	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4078	Acquired_Actavis_00835648	Action Stat for Oxycodone HCL ER Tablets	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4079	Acquired_Actavis_01389540	Review and Approval of Drug Advertising for All ANDA Prescription Drug Products	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4080	TEVA_OK_03325048	Oxymorphone Hydrochloride availability announcement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4081	TEVA_OK_03325039	Fentanyl Reservoir System Mailer	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4082	TEVA_OK_03325043	Hydrocodone Bitartrate and Acetaminophen Availability Announcement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4083	TEVA_OK_03325038	Buprenorphine Naloxone Journal Advertisement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4084	TEVA_OK_06205271	Cephalon Policy on Identifying Called on Universe of Physicians in Connection with Promotional Activities	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4085	TEVA_OK_00510540	Cephalon Targeting and "Do Not Detail" Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
4086	TEVA_OK_01358396	Cephalon Targeting Assessment and Call Activity Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4087	TEVA_OK_00510366	Cephalon Targeting Assessment and Call Activity Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4088	TEVA_OK_00098645	Cephalon Targeting Assessment and Call Activity	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4089	TEVA_OK_00097186	Cephalon Targeting Assessment and Call Activity	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4090	TEVA_OK_01126023	Teva DNC Exemption Process	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4091	TEVA_OK_01060432	Teva Do Not Call Form	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4092	TEVA_OK_01082624	Email chain from Jim Reilly	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4093	TEVA_OK_00510823	Teva Targeting Assessment and Call Activity	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4094	TEVA_OK_00891848	Sales Operations "Do Not Promote/Do Not Call Documentation Policy"	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
4095	TEVA_OK_00510540	Cephalon Targeting & Do Not Detail Policy In Connection With Promotional Activities	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5000	TEVA_OK_05454837	Cephalon Corporate Compliance Program Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5001	TEVA_OK_09617938	Cephalon Code of Conduct	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5002	TEVA_OK_06205249	Cephalon Sales Policy Handbook	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5003	TEVA_OK_00852658	Cephalon Sales Policy Handbook	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5004	TEVA_OK_00510826	Teva Code of Business Conduct	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
5005	TEVA_OK_03529966	Cephalon 2007 Sales Policy Handbook	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5006	TEVA_OK_00510295	Standards of Global Business Practices	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5007	TEVA_OK_00510245	Cephalon Reporting and Investigations of Misconduct	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5008	TEVA_OK_01358751	Charter of Cephalon's Global Compliance Committee	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5009	TEVA_OK_00038710	Cephalon Global Compliance Report	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5010	TEVA_OK_01325965	Cephalon Global Compliance New Employee Orientation	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5011	TEVA_OK_00510295	Cephalon Standards of Global Business Practices	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5012	TEVA_OK_00509965	Cephalon Good Business Practices Field Guide	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5013	TEVA_OK_01340685	Compliance Overview Initial Training Class Presentation	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5014	TEVA_OK_00050930	Compliance Overview Initial Training Class Presentation	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5015	TEVA_OK_00851758	Cephalon Global Compliance Department	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5016	TEVA_OK_00510810	Teva Reporting and Investigations of Misconduct	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5017	TEVA_OK_00510028	Cephalon Incident Management	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5018	TEVA_OK_00510776	Teva Incident Management	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5019	TEVA_OK_00509933	Field Force Ride-Along Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
5020	TEVA_OK_00050930	Compliance Overview: Initial Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5021	TEVA_OK_00098244	Report on Independent Review Organization's Engagement: Procedures, Findings and Recommendations	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5022	TEVA_OK_00631995	Teva Standard Operating Procedures Manual	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5023	TEVA_OK_00095450	CIA Annual Report	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5024	TEVA_OK_00097167	CIA Annual Report	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5025	TEVA_OK_00098241	List of CIA-Required Trainings Attended by Company Employees	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5026	TEVA_OK_00098697	Report on Independent Review Organization Engagement Procedures, Findings and Recommendations	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5027	TEVA_OK_00099196	CIA Annual Report	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5028	TEVA_OK_01313975	Exit Meeting Presentation for OIG	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5029	TEVA_OK_01321141	Letter from OIG to Tricia Glover	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5030	TEVA_OK_07959822	Effectiveness of Cephalon's Global Compliance Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5031	TEVA_OK_00510118	Cephalon Political Activities and Lobbying Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5032	TEVA_OK_01149188	Cephalon Management Readiness Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5033	TEVA_OK_00510113	Cephalon Patient Safety Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5034	TEVA_OK_00510696	WLF: Dissemination of Peer-Reviewed Reprints and Reference Textbooks	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
5035	TEVA_OK_00842976	Cephalon MIRF Monitoring Procedure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5036	TEVA_OK_01256793	Government & Public Policy PPT	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5037	TEVA_OK_01257102	Government Affairs and Public Policy at Teva	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5038	TEVA_OK_13245920	Consultants and Consulting Services Spreadsheet	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5039	TEVA_OK_00007783	Year Two CIA Specific New Hire Course	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5040	TEVA_OK_00504282	Speakers Bureau Business Rationale Application	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5041	TEVA_OK_01309466	Submission of Medical Information Requests	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5042	TEVA_OK_02787288	Medical Information Request Monitoring	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5043	Acquired_Actavis_01440569	Corporate Standard Operating Procedure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5044	TEVA_OK_00098098	CIA Annual Report Year 1	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5045	TEVA_OK_00098625	CIA Annual Report Year 2	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5046	TEVA_OK_00510446	US Sales and Marketing Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5047	TEVA_OK_00848260	Training Process for Members of the Sales Organization	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5048	TEVA_OK_03330056	Cephalon Standards of Business Conduct	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5049	TEVA_OK_06167019	Mid-Year Compliance Update	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
5050	TEVA_OK_07969618	Policy on Gifts, Meals, and Entertainment for Physicians and Other Healthcare Practitioners	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5051	TEVA_OK_11581963	inVentiv Health Care Compliance Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5052	TEVA_OK_11621107	Policy on Providing Reimbursement Information to Customers	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5053	TEVA_OK_11621127	Policy on Advertising and Promotional Materials and Activities	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5054	TEVA_OK_11621144	Policy Re: Sample Management	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5055	TEVA_OK_11621152	Policy on Preceptorships	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5056	TEVA_OK_11621156	Policy on Funding to Support Independent, Third-Party Educational or Scientific Meetings	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5057	TEVA_OK_11621169	Policy on Grants or Support that are not for Independent Medical Education	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5058	TEVA_OK_11621173	Policy Re: Employee Reporting of Adverse Events, Product Complaints, Tampering, Adulteration and/or Diversion	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5059	TEVA_OK_00999102	Board of Directors Meeting	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5060	TEVA_OK_01326313	Teva U.S. Specialty Medicines Compliance Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5061	TEVA_OK_01312043	Integrity In Focus: Products and Promotion	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
5062	Acquired_Actavis_01493361	Actavis Compliance: General Training (Undated)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
6000	TEVA_OK_08481232	Cephalon Promotional Review Process Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
6001	TEVA_OK_00510173	Cephalon Promotional Review Process	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
6002	TEVA_OK_00510800	Promotion and Advertising Review (PARC) Process	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
6003	TEVA_OK_00509697	Cephalon Activity Review & Evaluation (CARE) Process	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
6004	TEVA_OK_00097186	Teva Centralized Activity Review and Evaluation	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
6005	TEVA_OK_00509697	Cephalon Activity Review & Evaluation (CARE) Process	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7000	TEVA_OK_06205274	Cephalon Policy Regarding Medical Information Request Forms	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7001	TEVA_OK_00510347	Cephalon Submission of Medical Requests	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7002	TEVA_OK_00510821	Teva Submission of Medical Requests	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7003	TEVA_OK_00509905	Cephalon Employee Compensation Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7004	TEVA_OK_00097186	Teva Employee Incentive Compensation Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7005	TEVA_OK_11508440	Cephalon Handling Unsolicited Medical Communications (SOP-0321-D08) (Feb. 2005)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7006	TEVA_OK_01850023	Cephalon Guide for Discussions with Physicians, May 2004	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7007	TEVA_OK_00510087	Cephalon Medical Information Request Monitoring (GC-210)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7008	TEVA_OK_00510785	Teva Medical Information Request Monitoring (Compliance Procedure-300)(Jul. 2012)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7009	TEVA_OK_00510787	Teva Medical Science Liaison Policy (US Policy-210), (Jul. 2012)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
7010	TEVA_OK_04434687	Report from FDA Office of Surveillance & Epidemiology Fentora RiskMAP & Postmarketing Review Team to FDA Anesthetic & Life Support Drugs Advisory Committee Members & FDA Drug Safety & Risk Management Advisory Committee Members	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7011	TEVA_OK_04434687	Overview of ALSDAC sNDA Meeting	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7012	TEVA_OK_01114507	Correspondence discussed in Letter from Penny Levin, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA, with sNDA Briefing Package	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7013	TEVA_OK_00283296	Fentora sNDA Briefing Book	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7014	TEVA_OK_00288476	Letter from Penny Levin, Cephalon, to Robert Rappaport, FDA, General Correspondence Information Package – Type A Meeting	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7015	TEVA_OK_00372702	Letter from Susan Franks, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7016	TEVA_OK_01365329	Regulatory Affairs Project Update	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
7017	TEVA_OK_08504578	Actiq (Oral Transmucosal Fentanyl Citrate, OTFC) Official Correspondence Log	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
8000	TEVA_OK_00097186	Teva Independent Medical Education Grants US Policy-205 (JULY 2012)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
8001	TEVA_OK_01324445	Cephalon Company Giving Policy (July 1, 2008)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
8002	TEVA_OK_00509702	Cephalon Charitable Contributions Policy, (July 1 2008)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
8003	TEVA_OK_00509705	Cephalon Charitable Contributions Procedure, (Aug. 14, 2009).	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
8004	TEVA_OK_03530000	Cephalon Policy on Third-Party Funding Requests to Support Independent Medical Education Program, (Oct. 2006).	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9000	TEVA_OK_02975560	Cephalon Speaker Bureau Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9001	TEVA_OK_03530035	Sales Policy Handbook – Policy on Promotional Meetings	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9002	TEVA_OK_00853718	Cephalon Speaker Bureau Management Procedure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9003	TEVA_OK_00097186	Cephalon Speaker Program Management	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9004	TEVA_OK_00857135	Cephalon Marketing Speaker Bureau	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9005	TEVA_OK_05043159	Cephalon Cogenix LLC Speaker Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9006	TEVA_OK_00793228	CSP Planning System User Manual	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9007	TEVA_OK_05230325	Actiq Speaker Bureau Training Guidelines	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9008	TEVA_OK_04352086	Actiq Speaker Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9009	TEVA_OK_01008963	Cephalon Pain Franchise Speaker Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9010	TEVA_OK_01041669	Cephalon Pain Franchise Speaker Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9011	TEVA_OK_00982132	Cephalon Pain Franchise Fentora Speaker Training	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9012	TEVA_OK_01027414	Abuse, Addiction, and Diversion of Controlled Substances	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9013	TEVA_OK_04766774	Fentora Secure Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J.&J and Janssen reserve the right to object at trial to any Teva exhibit because J.&J and Janssen have not had the opportunity to review them)
9014	TEVA_OK_05605945	Cephalon-Sponsored CMEs	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9015	TEVA_OK_00097186	Teva Payments to Healthcare Professionals Involved in Scientific and Medical-Related Activities	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9016	TEVA_OK_05455479	American Pain Foundation Educational Grant Request and Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9017	TEVA_OK_05456765	American Pain Society Educational Grant Request and Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9018	TEVA_OK_06172432	Letter from Cephalon to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9019	TEVA_OK_00642745	Speaker Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9020	TEVA_OK_01323973	Portenoy Advisory Board Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9021	TEVA_OK_03612864	Portenoy Advisory Board Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9022	TEVA_OK_09386711	Portenoy Collaboration Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9023	TEVA_OK_05230328	Cephalon Speaker Identification and Development	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9024	TEVA_OK_05040313	Portenoy Preceptor Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9025	TEVA_OK_03201585	Perry Fine Consulting Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9026	TEVA_OK_00105227	MediCom Medical Education Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9027	TEVA_OK_01855191	Grant Request from MediCom Worldwide Inc.	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9028	TEVA_OK_00105111	2004 Medical Education Agreement for CME Lecture Series	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
9029	TEVA_OK_01548846	Medical Education Grant through Fusion Medical Education	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9030	TEVA_OK_00104943	Independent Educational Program Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9031	TEVA_OK_01489972	Independent Educational Program Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9032	TEVA_OK_01494755	Independent Educational Program Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9033	TEVA_OK_01287333	Independent Educational Program Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9034	TEVA_OK_05455479	Medical Education Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9035	TEVA_OK_01473137	Educational Grant Draft Request	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9036	TEVA_OK_03201991	Unrestricted Educational Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9037	TEVA_OK_03202587	Unrestricted Educational Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9038	TEVA_OK_01465973	Unrestricted Educational Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9039	TEVA_OK_01498198	Teva SOP on US Medical Education Grants	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9040	TEVA_OK_01498209	Grant Review Check List	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9041	TEVA_OK_01497603	Letter of Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9042	TEVA_OK_01497231	Letter of Independence	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9043	TEVA_OK_01498888	US Policy-205	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
9044	TEVA_OK_01324842	Independent Medical Education Grants Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9045	TEVA_OK_00510687	Cephalon Policy on Third-Party Grant Requests	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9046	TEVA_OK_00010978	Pain Management: Understanding Opioids and Managing Their Risks, Overview of Responsible Prescribing	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9047	TEVA_OK_01287298	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9048	TEVA_OK_01466060; TEVA_OK_01465950	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9049	TEVA_OK_01469340; TEVA_OK_05455479	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9050	TEVA_OK_01484031	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9051	TEVA_OK_01484644	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9052	TEVA_OK_01490234	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9053	TEVA_OK_01490237	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9054	TEVA_OK_01495170	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9055	TEVA_OK_01495251	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9056	TEVA_OK_01495446	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9057	TEVA_OK_01498434	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9058	TEVA_OK_01544515	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
9059	TEVA_OK_01544602	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9060	TEVA_OK_01545205	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9061	TEVA_OK_01548870	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9062	TEVA_OK_03201322	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9063	TEVA_OK_05050796	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9064	TEVA_OK_06133380	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
9065	TEVA_OK_06133620	Independent Medical Education Grant Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
10000	Publicly Available	TEVA Corporate Structure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
10001	TEVA_OK_02269143	Pharmaceutical Operations Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
10002	TEVA_OK_00437922	Cephalon 2008 Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
10003	TEVA_OK_00437983	Cephalon 2009 Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
10004	TEVA_OK_00438037	Cephalon 2010 Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
10005	TEVA_OK_00500265	Teva 2015 Organizational Chart	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11000	TEVA_OK_01285369	TEVA SOP-8279	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11001	TEVA_OK_01285399	TEVA SOP 8279	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
11002	TEVA_OK_01285361	TEVA SOP-8277	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11003	TEVA_OK_01285382	TEVA SOP-8277	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11004	TEVA_OK_01285420	TEVA SOP-8489	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11005	TEVA_OK_01285376	TEVA SOP-8280	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11006	TEVA_OK_01285408	TEVA SOP-8280	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11007	TEVA_OK_01285356	TEVA SOP 8278	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11008	TEVA_OK_01285392	TEVA SOP 8278	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11009	TEVA_OK_01229493	SORDS Summary	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11010	TEVA_OK_00510249	Cephalon Reporting of Adverse Events, Product Complaints and Suspected Diversions	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11011	TEVA_OK_00355000	Actiq Risk Management Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11012	TEVA_OK_01405115	"Dear Healthcare Provider: Important Safety Information for Fentora"	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11013	TEVA_OK_00691645	Product Bulletin	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11014	TEVA_OK_00597337	"Dear Healthcare Provider"	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11015	TEVA_OK_00372705	Actiq & Fentora Proposed Risk Evaluation & Mitigation Strategy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11016	TEVA_OK_00908803	Teva Policy Statement on Suspicious Order Monitoring	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
11017	TEVA_OK_01225787	Controlled Substance Order Monitoring Procedure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11018	TEVA_OK_01229518	DEA Affairs Controlled Substance Customer Knowledge Policy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11019	TEVA_OK_01287369	SOP-0013489	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11020	TEVA_OK_00355080	Actiq® Risk Management Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11021	TEVA_OK_00355080	Chronology of FDA-Approved Changes to the Actiq Risk Management Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11022	TEVA_OK_00355000	Actiq Risk Management Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11023	TEVA_OK_01286478	Quality Assurance Memorandum	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11024	TEVA_OK_00027590	Timeline of Events Leading Up to the REMS Requirement for Opioid Analgesics	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11025	TEVA_OK_01564736	Actiq Prior Approval Supplement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11026	TEVA_OK_00354524	Actiq Proposed Risk Management Program	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11027	TEVA_OK_00088190	Amendment to S-020	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11028	TEVA_OK_00088735	Actiq Risk Management Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11029	TEVA_OK_00082019	Letter from Penny S. Levin to Robert Rappaport FDA	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11030	TEVA_OK_00082019	Fentora Risk Minimization Plan	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11031	TEVA_OK_00047363	Fentora sNDA RiskMAP Tools Review Meeting:	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
11032	TEVA_OK_04434687	Report from FDA Office of Surveillance & Epidemiology Fentora RiskMAP & Postmarketing Review Team	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11033	TEVA_OK_00363898	New Supplement for NDA 20-747: Proposed Risk Evaluation & Mitigation Strategy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11034	TEVA_OK_03466998	Teva REMS – Regulatory Affairs Lunch & Learn)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11035	TEVA_OK_08753816	Summary of Changes – Actiq REMS	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11036	TEVA_OK_00372569	Actiq Risk Evaluation & Mitigation Strategy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11037	TEVA_OK_00372697	Summary of Changes – Proposed Actiq REMS	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11038	TEVA_OK_05066118	Charter Agreement of the TIRF REMS Industry Group	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11039	TEVA_OK_01407411	Actiq & Fentora Risk Evaluation & Mitigation Strategy	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11040	TEVA_OK_00620176	REMS Operations Global Pharmacovigilance & Regulatory Slide Deck	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11041	TEVA_OK_01286886	TIRF REMS Advisory Committee Briefing	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11042	TEVA_OK_03466998	Teva REMS – Regulatory Affairs Lunch & Learn	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11043	TEVA_OK_04184525	Supplemental Approval for Fentora REMS	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11044	TEVA_OK_08775238	SOP-0001053	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11045	TEVA_OK_11031778	Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation & Mitigation Strategy (REMS)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11046	Publicly Available	TIRF REMS Access Education Program for Prescribers and Pharmacists	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
11047	Publicly Available	TIRF REMS Prescriber Enrollment Form	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11048	Publicly Available	TIRF REMS Patient-Prescriber Agreement Form	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11049	Publicly Available	TIRF REMS Corporate Pharmacy Enrollment Form	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11050	TEVA_OK_08083541	TIRF REMS Prescriber Enrollees	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11051	TEVA_OK_08083542	TIRF REMS Pharmacy Enrollees	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11052	TEVA_OK_08083543	TIRF REMS Patient Enrollees	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11053	TEVA_OK_08083544	TIRF REMS Prescriptions	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11054	TEVA_OK_13730408- TEVA_OK14085611	TIRF REMS Supporting Documents	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11055	TEVA_OK_01226424	Watson-cSOP-11-004-Revision 004	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12000	TEVA_OK_00510252	Review Process for Investigator Sponsored Studies	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12001	TEVA_OK_08952668	Table of Clinical Studies: Table 2: Fentora (fentanyl buccal tablet)	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12002	TEVA_OK_07849964	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12003	TEVA_OK_07849965	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12004	TEVA_OK_07849966	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12005	TEVA_OK_07849967	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
12006	TEVA_OK_07849968	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12007	TEVA_OK_07849976	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12008	TEVA_OK_07887401	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12009	TEVA_OK_07887402	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12010	TEVA_OK_07887410	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12011	TEVA_OK_07887419	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12012	TEVA_OK_07887486	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12013	TEVA_OK_07887520	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12014	TEVA_OK_07887561	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12015	TEVA_OK_07887678	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12016	TEVA_OK_07887686	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12017	TEVA_OK_07887692	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12018	TEVA_OK_07887699	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12019	TEVA_OK_07889923	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12020	TEVA_OK_07896839	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
12021	TEVA_OK_07899319	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12022	TEVA_OK_07906665	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12023	TEVA_OK_07906666	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12024	TEVA_OK_07906679	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12025	TEVA_OK_07908444	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12026	TEVA_OK_07911018	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12027	TEVA_OK_07912025	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12028	TEVA_OK_07914883	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12029	TEVA_OK_07914888	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12030	TEVA_OK_07917719	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12031	TEVA_OK_07917724	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
12032	TEVA_OK_07924701	Actiq and Fentora Clinical Study Reports	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13000	TEVA_OK_00116233	Making Pain Talk Painless	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13001	TEVA_OK_01098122	Email from Michael Richardson to Terrence Terifay	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13002	TEVA_OK_01570967	Letter from Cephalon to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13003	TEVA_OK_01517005	Unbranded brochure	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13004	TEVA_OK_00502673	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13005	TEVA_OK_00502680	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13006	TEVA_OK_00502716	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13007	TEVA_OK_00502753	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13008	TEVA_OK_00502790	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13009	TEVA_OK_00502801	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13010	TEVA_OK_00503051	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13011	TEVA_OK_00503061	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13012	TEVA_OK_00503067	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13013	TEVA_OK_00503071	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13014	TEVA_OK_00503093	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13015	TEVA_OK_00503116	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13016	TEVA_OK_00503153	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13017	TEVA_OK_00503198	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13018	TEVA_OK_00503217	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13019	TEVA_OK_00503255	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13020	TEVA_OK_00503279	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13021	TEVA_OK_00503308	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13022	TEVA_OK_00503337	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13023	TEVA_OK_00503391	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13024	TEVA_OK_00503438	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13025	TEVA_OK_00503536	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13026	TEVA_OK_00503597	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13027	TEVA_OK_00503638	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13028	TEVA_OK_00503685	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13029	TEVA_OK_00503740	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13030	TEVA_OK_00503787	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13031	TEVA_OK_00503902	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13032	TEVA_OK_00503945	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13033	TEVA_OK_00503995	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13034	TEVA_OK_00504103	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13035	TEVA_OK_00504149	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13036	TEVA_OK_00504172	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13037	TEVA_OK_00504195	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13038	TEVA_OK_00504218	Actiq Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13039	TEVA_OK_00008926	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13040	TEVA_OK_00008968	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13041	TEVA_OK_00009028	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13042	TEVA_OK_00009063	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13043	TEVA_OK_00009066	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13044	TEVA_OK_00009094	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13045	TEVA_OK_00009113	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13046	TEVA_OK_00009184	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
13047	TEVA_OK_00009266	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13048	TEVA_OK_00009382	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13049	TEVA_OK_00009434	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13050	TEVA_OK_00009494	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13051	TEVA_OK_00009532	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13052	TEVA_OK_00009553	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13053	TEVA_OK_00009560	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13054	TEVA_OK_00009630	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13055	TEVA_OK_00009671	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13056	TEVA_OK_00009678	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13057	TEVA_OK_00009716	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13058	TEVA_OK_00009768	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13059	TEVA_OK_00009776	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13060	TEVA_OK_00009786	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13061	TEVA_OK_00009795	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13062	TEVA_OK_00009806	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13063	TEVA_OK_00009859	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13064	TEVA_OK_00009869	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13065	TEVA_OK_00009878	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13066	TEVA_OK_00009912	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13067	TEVA_OK_00009928	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13068	TEVA_OK_00010018	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13069	TEVA_OK_00010028	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13070	TEVA_OK_00010045	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13071	TEVA_OK_00010151	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13072	TEVA_OK_00010161	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13073	TEVA_OK_00010254	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13074	TEVA_OK_00010306	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13075	TEVA_OK_00010316	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13076	TEVA_OK_00010395	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13077	TEVA_OK_00010403	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13078	TEVA_OK_00010450	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13079	TEVA_OK_00010461	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13080	TEVA_OK_00010482	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13081	TEVA_OK_00010591	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13082	TEVA_OK_00010640	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13083	TEVA_OK_00010804	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13084	TEVA_OK_00010836	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13085	TEVA_OK_00010840	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13086	TEVA_OK_00010858	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13087	TEVA_OK_00010904	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13088	TEVA_OK_00010920	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13089	TEVA_OK_00010927	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13090	TEVA_OK_00010939	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13091	TEVA_OK_00010950	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13092	TEVA_OK_00010978	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13093	TEVA_OK_00011104	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13094	TEVA_OK_00011162	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13095	TEVA_OK_00011244	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13096	TEVA_OK_00011251	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13097	TEVA_OK_00011325	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13098	TEVA_OK_00011334	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13099	TEVA_OK_00011341	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13100	TEVA_OK_00011350	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13101	TEVA_OK_00011357	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13102	TEVA_OK_00011370	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13103	TEVA_OK_00011377	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13104	TEVA_OK_00011390	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13105	TEVA_OK_00011398	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13106	TEVA_OK_00011415	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13107	TEVA_OK_00011417	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13108	TEVA_OK_00011525	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13109	TEVA_OK_00011538	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13110	TEVA_OK_00011558	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13111	TEVA_OK_00011575	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13112	TEVA_OK_00011604	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13113	TEVA_OK_00011765	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13114	TEVA_OK_00011789	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13115	TEVA_OK_00011804	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13116	TEVA_OK_00011817	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13117	TEVA_OK_00011873	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13118	TEVA_OK_00011880	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13119	TEVA_OK_00011904	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13120	TEVA_OK_00011953	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13121	TEVA_OK_00012022	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13122	TEVA_OK_00012036	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13123	TEVA_OK_00012063	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13124	TEVA_OK_00012069	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13125	TEVA_OK_00012076	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13126	TEVA_OK_00012085	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13127	TEVA_OK_00012093	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13128	TEVA_OK_00012106	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13129	TEVA_OK_00012138	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13130	TEVA_OK_00012144	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13131	TEVA_OK_00012151	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13132	TEVA_OK_00012160	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13133	TEVA_OK_00012170	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13134	TEVA_OK_00012180	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13135	TEVA_OK_00012191	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13136	TEVA_OK_00012216	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13137	TEVA_OK_00012225	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13138	TEVA_OK_00012339	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13139	TEVA_OK_00012346	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13140	TEVA_OK_00012355	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13141	TEVA_OK_00012370	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13142	TEVA_OK_00012404	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13143	TEVA_OK_00012421	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13144	TEVA_OK_00012513	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13145	TEVA_OK_00012583	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13146	TEVA_OK_00012593	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13147	TEVA_OK_00012673	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13148	TEVA_OK_00012720	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13149	TEVA_OK_00012738	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13150	TEVA_OK_00012759	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13151	TEVA_OK_00012799	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13152	TEVA_OK_00012841	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13153	TEVA_OK_00013082	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13154	TEVA_OK_00013095	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13155	TEVA_OK_00013110	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13156	TEVA_OK_00013120	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13157	TEVA_OK_00013172	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13158	TEVA_OK_00013183	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13159	TEVA_OK_00013200	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13160	TEVA_OK_00013209	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13161	TEVA_OK_00013217	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13162	TEVA_OK_00013463	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13163	TEVA_OK_00013486	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13164	TEVA_OK_00013508	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13165	TEVA_OK_00013531	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13166	TEVA_OK_00013603	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13167	TEVA_OK_00013611	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13168	TEVA_OK_00013622	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13169	TEVA_OK_00013672	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13170	TEVA_OK_00013704	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13171	TEVA_OK_00013717	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13172	TEVA_OK_00013782	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13173	TEVA_OK_00013859	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13174	TEVA_OK_00013867	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13175	TEVA_OK_00013891	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13176	TEVA_OK_00013901	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13177	TEVA_OK_00013930	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13178	TEVA_OK_00013959	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13179	TEVA_OK_00013967	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13180	TEVA_OK_00013988	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13181	TEVA_OK_00014042	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13182	TEVA_OK_00014064	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13183	TEVA_OK_00014085	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13184	TEVA_OK_00014174	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13185	TEVA_OK_00014272	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13186	TEVA_OK_00014333	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13187	TEVA_OK_00014429	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13188	TEVA_OK_00014470	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13189	TEVA_OK_00014517	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13190	TEVA_OK_00014590	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13191	TEVA_OK_00014618	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13192	TEVA_OK_00014673	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13193	TEVA_OK_00014697	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13194	TEVA_OK_00014744	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13195	TEVA_OK_00014859	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13196	TEVA_OK_00014902	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13197	TEVA_OK_00014934	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13198	TEVA_OK_00014984	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13199	TEVA_OK_00015092	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13200	TEVA_OK_00015138	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13201	TEVA_OK_00015161	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13202	TEVA_OK_00015180	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13203	TEVA_OK_00015203	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13204	TEVA_OK_00015221	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13205	TEVA_OK_00015239	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13206	TEVA_OK_00015258	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13207	TEVA_OK_00015279	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13208	TEVA_OK_00015304	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13209	TEVA_OK_00015341	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13210	TEVA_OK_00015359	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13211	TEVA_OK_00015379	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13212	TEVA_OK_00015414	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13213	TEVA_OK_00015435	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13214	TEVA_OK_00015471	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13215	TEVA_OK_00015509	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13216	TEVA_OK_00015527	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13217	TEVA_OK_00015545	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13218	TEVA_OK_00015576	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13219	TEVA_OK_00015662	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13220	TEVA_OK_00015747	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13221	TEVA_OK_00015774	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13222	TEVA_OK_00015800	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13223	TEVA_OK_00015907	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13224	TEVA_OK_00015969	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13225	TEVA_OK_00015989	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13226	TEVA_OK_00016008	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13227	TEVA_OK_00016027	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13228	TEVA_OK_00016087	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13229	TEVA_OK_00016189	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13230	TEVA_OK_00016213	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13231	TEVA_OK_00016235	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13232	TEVA_OK_00016262	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13233	TEVA_OK_00016383	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13234	TEVA_OK_00016449	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13235	TEVA_OK_00016468	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13236	TEVA_OK_00016472	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13237	TEVA_OK_00016492	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13238	TEVA_OK_00016604	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13239	TEVA_OK_00016632	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13240	TEVA_OK_00016639	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13241	TEVA_OK_00016697	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13242	TEVA_OK_00016781	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
13243	TEVA_OK_00016806	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13244	TEVA_OK_00016815	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13245	TEVA_OK_00016855	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13246	TEVA_OK_00016903	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13247	TEVA_OK_00016941	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13248	TEVA_OK_00016946	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13249	TEVA_OK_00016951	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13250	TEVA_OK_00016964	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13251	TEVA_OK_00017017	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13252	TEVA_OK_00017032	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13253	TEVA_OK_00017051	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13254	TEVA_OK_00017060	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
13255	TEVA_OK_00017155	Fentora Marketing Materials Submitted to DDMAC	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
14000	TEVA_OK_03475218	Teva Pharmaceutical Industries Ltd and Allergan PLC Agreement	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
14001	TEVA_OK_03321424	Agreement between Purdue Pharma L.P. and Teva Pharmaceuticals USA, INC.	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
15000	Publicly Available	Boston University, Study: Friends, Relatives Biggest Source of Opiate Painkillers	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
15001	Publicly Available	Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16000	Exhibit 1	Stoneking, Jeffrey/Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16001	Exhibit 2	Stoneking, Jeffrey/Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16002	Exhibit 3	Stoneking, Jeffrey/Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16003	Exhibit 4	Stoneking, Jeffrey/Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16004	Exhibit 5	Stoneking, Jeffrey/Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16005	Exhibit 6	Stoneking, Jeffrey/Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16006	Exhibit 7	Stoneking, Jeffrey/Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16007	Exhibit 8	Stoneking, Jeffrey/Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16008	Exhibit 9	Stoneking, Jeffrey/Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16009	Exhibit 10	Stonking, Jeffrey Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16010	Exhibit 11	Stonking, Jeffrey Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16011	Exhibit 12	Stonking, Jeffrey Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16012	Exhibit 13	Stonking, Jeffrey Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16013	Exhibit 14	Stonking, Jeffrey Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16014	Exhibit 15	Stonking, Jeffrey Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16015	Exhibit 16	Stonking, Jeffrey Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16016	Exhibit 17	Stonking, Jeffrey Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16017	Exhibit 18	Stonking, Jeffrey Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16018	Exhibit 19	Stonking, Jeffrey Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16019	Exhibit 20	Stonking, Jeffrey Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16020	Exhibit 21	Stonking, Jeffrey/Exhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16021	Exhibit 22	Stonking, Jeffrey/Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16022	Exhibit 23	Stonking, Jeffrey/Exhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16023	Exhibit 1	Castleberry, Clint/Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16024	Exhibit 2	Castleberry, Clint/Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16025	Exhibit 3	Castleberry, Clint/Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16026	Exhibit 4	Castleberry, Clint/Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16027	Exhibit 5	Castleberry, Clint/Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16028	Exhibit 6	Castleberry, Clint/Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16029	Exhibit 7	Castleberry, Clint/Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16030	Exhibit 8	Castleberry, Clint/Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16031	Exhibit 9	Castleberry, ClintExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16032	Exhibit 10	Castleberry, ClintExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16033	Exhibit 11	Castleberry, ClintExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16034	Exhibit 12	Castleberry, ClintExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16035	Exhibit 13	Castleberry, ClintExhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16036	Exhibit 14	Castleberry, ClintExhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16037	Exhibit 15	Castleberry, ClintExhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16038	Exhibit 16	Castleberry, ClintExhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16039	Exhibit 17	Castleberry, ClintExhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16040	Exhibit 18	Castleberry, ClintExhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16041	Exhibit 1	Hawkins, JessicaExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16042	Exhibit 2	Hawkins, JessicaExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16043	Exhibit 3	Hawkins, JessicaExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16044	Exhibit 4	Hawkins, JessicaExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16045	Exhibit 5	Hawkins, JessicaExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16046	Exhibit 6	Hawkins, JessicaExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16047	Exhibit 7	Hawkins, JessicaExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16048	Exhibit 8	Hawkins, JessicaExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16049	Exhibit 9	Hawkins, JessicaExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16050	Exhibit 10	Hawkins, JessicaExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16051	Exhibit 12	Hawkins, JessicaExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16052	Exhibit 13	Hawkins, JessicaExhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16053	Exhibit 14	Hawkins, JessicaExhibit 14		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16054	Exhibit 15	Hawkins, Jessica Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16055	Exhibit 16	Hawkins, Jessica Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16056	Exhibit 17	Hawkins, Jessica Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16057	Exhibit 18	Hawkins, Jessica Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16058	Exhibit 19	Hawkins, Jessica Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16059	Exhibit 1	Harrell, Anetta Louise Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16060	Exhibit 2	Harrell, Anetta Louise Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16061	Exhibit 3	Harrell, Anetta Louise Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16062	Exhibit 4	Harrell, Anetta Louise Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16063	Exhibit 5	Harrell, Anetta Louise Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16064	Exhibit 6	Harrell, Anetta Louise Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16065	Exhibit 7	Harrell, Anetta Louise Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16066	Exhibit 8	Harrell, Anetta Louise Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16067	Exhibit 9	Harrell, Anetta Louise Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16068	Exhibit 10	Harrell, Anetta Louise Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16069	Exhibit 11	Harrell, Anetta Louise Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16070	Exhibit 12	Harrell, Anetta Louise Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16071	Exhibit 13	Harrell, Anetta Louise Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16072	Exhibit 14	Harrell, Anetta Louise Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16073	Exhibit 15	Harrell, Anetta Louise Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16074	Exhibit 16	Harrell, Anetta Louise Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16075	Exhibit 17	Harrell, Anetta Louise Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16076	Exhibit 18	Harrell, Anetta Louise Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16077	Exhibit 19	Harrell, Anetta Louise Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16078	Exhibit 20	Harrell, Anetta Louise Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16079	Exhibit 21	Harrell, Anetta Louise Exhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16080	Exhibit 22	Harrell, Anetta Louise Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16081	Exhibit 23	Harrell, Anetta Louise Exhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16082	Exhibit 24	Harrell, Anetta Louise Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16083	Exhibit 25	Harrell, Anetta Louise Exhibit 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16084	Exhibit 26	Harrell, Anetta Louise Exhibit 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16085	Exhibit 27	Harrell, Anetta Louise Exhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16086	Exhibit 28	Harrell, Anetta Louise Exhibit 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16087	Exhibit 5	Prestar, Paul Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16088	Exhibit 6	Preslar, Paul Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16089	Exhibit 11	Preslar, Paul Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16090	Exhibit 12	Preslar, Paul Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16091	Exhibit 14	Preslar, Paul Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16092	Exhibit 16	Preslar, Paul Exhibit 16		
16093	Exhibit 17	Preslar, Paul Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16094	Exhibit 18	Preslar, Paul Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16095	Exhibit 19	Preslar, Paul Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16096	Exhibit 20	Preslar, Paul Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16097	Exhibit 22	Preslar, Paul Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16098	Exhibit 24	Preslar, Paul Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16099	Exhibit 25	Preslar, Paul Exhibit 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16100	Exhibit 27	Preslar, PaulExhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16101	Exhibit 28	Preslar, PaulExhibit 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16102	Exhibit 29	Preslar, PaulExhibit 29	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16103	Exhibit 30	Preslar, PaulExhibit 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16104	Exhibit 31	Preslar, PaulExhibit 31	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16105	Exhibit 32	Preslar, PaulExhibit 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16106	Exhibit 33	Preslar, PaulExhibit 33	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16107	Exhibit 34	Preslar, PaulExhibit 34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16108	Exhibit 35	Preslar, PaulExhibit 35	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16109	Exhibit 36	Preslar, PaulExhibit 36	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16110	Exhibit 37	Preslar, PaulExhibit 37	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16111	Exhibit 38	Preslar, PaulExhibit 38	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16112	Exhibit 39	Preslar, PaulExhibit 39	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16113	Exhibit 40	Preslar, PaulExhibit 40	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16114	Exhibit 41	Preslar, PaulExhibit 41	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16115	Exhibit 42	Preslar, PaulExhibit 42	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16116	Exhibit 43	Preslar, PaulExhibit 43	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16117	Exhibit 44	Preslar, PaulExhibit 44	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16118	Exhibit 45	Preslar, PaulExhibit 45	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16119	Exhibit 46	Preslar, PaulExhibit 46	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16120	Exhibit 5	Osborne, James PatrickExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16121	Exhibit 6	Osborne, James PatrickExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16122	Exhibit 16	Osborne, James Patrick Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16123	Exhibit 21	Osborne, James Patrick Exhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16124	Exhibit 22	Osborne, James Patrick Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16125	Exhibit 24	Osborne, James Patrick Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16126	Exhibit 27	Osborne, James Patrick Exhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16127	Exhibit 32	Osborne, James Patrick Exhibit 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16128	Exhibit 35	Osborne, James Patrick Exhibit 35	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16129	exhibit 42	Osborne, James Patrick exhibit 42	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16130	Exhibit 45	Osborne, James Patrick Exhibit 45	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16131	Exhibit 47	Osborne, James Patrick Exhibit 47	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16132	Exhibit 48	Osborne, James Patrick Exhibit 48	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	